Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/28331615http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/28331615http://www.w3.org/2000/01/rdf-schema#comment"

Background

Predictive biomarkers for antibodies against programmed death 1 (PD-1) remain a major unmet need in metastatic melanoma. Specifically, response is seen in tumors that do not express programmed death ligand 1 (PD-L1), highlighting the need for a more sensitive biomarker. We hypothesize that capacity to express PD-L1, as assessed by an assay for a PD-L1 transcription factor, interferon regulatory factor 1 (IRF-1), may better distinguish patients likely to benefit from anti-PD-1 immunotherapy.

Methods

Samples from 47 melanoma patients that received nivolumab, pembrolizumab, or combination ipilimumab/nivolumab at Yale New Haven Hospital from May 2013 to March 2016 were collected. Expression of IRF-1 and PD-L1 in archival pre-treatment formalin-fixed, paraffin-embedded tumor samples were assessed by the AQUA method of quantitative immunofluorescence. Objective radiographic response (ORR) and progression-free survival (PFS) were assessed using modified RECIST v1.1 criteria.

Results

Nuclear IRF-1 expression was higher in patients with partial or complete response (PR/CR) than in patients with stable or progressive disease (SD/PD) (p = 0.044). There was an insignificant trend toward higher PD-L1 expression in patients with PR/CR (p = 0.085). PFS was higher in the IRF-1-high group than the IRF-1-low group (p = 0.017), while PD-L1 expression had no effect on PFS (p = 0.83). In a subset analysis, a strong association with PFS is seen in patients treated with combination ipilimumab and nivolumab (p = 0.0051).

Conclusions

As a measure of PD-L1 expression capability, IRF-1 expression may be a more valuable predictive biomarker for anti-PD-1 therapy than PD-L1 itself."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.org/dc/terms/identifier"doi:10.1186/s40425-017-0229-2"xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/author"Rimm D.L."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/author"Sznol M."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/author"Wong P.F."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/author"Moore L.M."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/author"Rehman J."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/author"Kluger H.M."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/author"Pelekanou V."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/author"Neumeister V.M."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/author"Gaule P."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/author"Smithy J.W."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/date"2017"xsd:gYear
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/name"J Immunother Cancer"xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/pages"25"xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/title"Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma."xsd:string
http://purl.uniprot.org/citations/28331615http://purl.uniprot.org/core/volume"5"xsd:string
http://purl.uniprot.org/citations/28331615http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/28331615
http://purl.uniprot.org/citations/28331615http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/28331615
http://purl.uniprot.org/uniprot/#_A0A0B6XK53-mappedCitation-28331615http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28331615
http://purl.uniprot.org/uniprot/#_A0A0B6XK11-mappedCitation-28331615http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28331615
http://purl.uniprot.org/uniprot/#_A0A1B1RS94-mappedCitation-28331615http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28331615
http://purl.uniprot.org/uniprot/#_A0A510GDD8-mappedCitation-28331615http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28331615
http://purl.uniprot.org/uniprot/#_B4DQF0-mappedCitation-28331615http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/28331615
▶